342 related articles for article (PubMed ID: 18381786)
1. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
Antoni CE; Kavanaugh A; van der Heijde D; Beutler A; Keenan G; Zhou B; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman DD; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen JS
J Rheumatol; 2008 May; 35(5):869-76. PubMed ID: 18381786
[TBL] [Abstract][Full Text] [Related]
2. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
3. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2.
van der Heijde D; Kavanaugh A; Gladman DD; Antoni C; Krueger GG; Guzzo C; Zhou B; Dooley LT; de Vlam K; Geusens P; Birbara C; Halter D; Beutler A
Arthritis Rheum; 2007 Aug; 56(8):2698-707. PubMed ID: 17665424
[TBL] [Abstract][Full Text] [Related]
4. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.
Kavanaugh A; Antoni CE; Gladman D; Wassenberg S; Zhou B; Beutler A; Keenan G; Burmester G; Furst DE; Weisman MH; Kalden JR; Smolen J; van der Heijde D
Ann Rheum Dis; 2006 Aug; 65(8):1038-43. PubMed ID: 16439444
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
6. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
[TBL] [Abstract][Full Text] [Related]
8. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
9. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.
Kavanaugh A; Krueger GG; Beutler A; Guzzo C; Zhou B; Dooley LT; Mease PJ; Gladman DD; de Vlam K; Geusens PP; Birbara C; Halter DG; Antoni C;
Ann Rheum Dis; 2007 Apr; 66(4):498-505. PubMed ID: 17114188
[TBL] [Abstract][Full Text] [Related]
10. Analysis of trial data for infliximab and golimumab: baseline C-reactive protein level and prediction of therapeutic response in patients with psoriatic arthritis.
Au SC; Ramirez-Fort MK; Gottlieb AB
Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1114-8. PubMed ID: 24339203
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
Genovese MC; Mease PJ; Thomson GT; Kivitz AJ; Perdok RJ; Weinberg MA; Medich J; Sasso EH;
J Rheumatol; 2007 May; 34(5):1040-50. PubMed ID: 17444593
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
Kavanaugh A; McInnes IB; Mease P; Krueger GG; Gladman D; van der Heijde D; Zhou Y; Lu J; Leu JH; Goldstein N; Beutler A
Ann Rheum Dis; 2014 Sep; 73(9):1689-94. PubMed ID: 24748630
[TBL] [Abstract][Full Text] [Related]
16. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
17. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data.
Coates LC; Helliwell PS
Arthritis Care Res (Hoboken); 2010 Jul; 62(7):965-9. PubMed ID: 20589696
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study.
Kavanaugh A; McInnes IB; Mease PJ; Krueger GG; Gladman DD; van der Heijde D; Mudivarthy S; Xu W; Mack M; Xu Z; Beutler A
Ann Rheum Dis; 2013 Nov; 72(11):1777-85. PubMed ID: 23161902
[TBL] [Abstract][Full Text] [Related]
19. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.
Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Dunn M; Tsuji W
J Rheumatol; 2006 Apr; 33(4):712-21. PubMed ID: 16463435
[TBL] [Abstract][Full Text] [Related]
20. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
